- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00458289
Efficacy of Phosphate Binding in Healthy Volunteers: Chewed Versus Crushed Lanthanum Carbonate
Patients with end-stage renal disease (ESRD) commonly have high concentrations of phosphorous, a mineral, in the blood (hyperphosphatemia). This is a result of their inability to excrete phosphorous by the kidneys. This in turn may result in the development of a condition known as secondary hyperparathyroidism and renal osteodystrophy or bone disease. As such, these patients often receive medications known as phosphate binders such as calcium carbonate or acetate, sevelamer, aluminum hydroxide and lanthanum carbonate to manage and treat hyperphosphatemia.
Lanthanum carbonate is a newly available phosphate binding agent that is effective in the management of hyperphosphatemia and preventing secondary hyperparathyroidism. It works in the gastrointestinal tract by binding to the phosphorus in the diet. ESRD patients taking lanthanum carbonate are counseled to chew the tablets completely before swallowing, with or immediately after meals. However, patients who are intubated or receiving nutrition via feeding tubes are unable to chew the tablets. For these patients, medications are commonly crushed and administered via the tube. Moreover, some patients prefer to crush the tablets and mix it with food instead of chewing. To date, it is not known if crushing the lanthanum carbonate tablets prior to administration and taking it with food would be as effective as chewing them.
The purpose of this study is to compare the efficacy of phosphate binding between chewed and crushed lanthanum carbonate tablets.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- University of Illinois at Chicago, Dept of Pharmacy Practice
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and women at least 18 years of age
- No clinically significant abnormal findings on clinical laboratory evaluation and medical history
- Within 15% of ideal body weight for height and build according to the Metropolitan Life tables5
- Women of child-bearing potential (premenopausal and not surgically sterilized) who have a negative pregnancy test
- Women who are sexually active must be using effective means of contraception
Exclusion Criteria:
- History of dysphagia or swallowing disorders
- Clinically significant illness within 3 months of study enrollment
- Concomitant use of medication that might interact with lanthanum carbonate
- Pregnant or intends to become pregnant within 30 days of completing the study
- Breast feeding
- Alcohol or controlled substance abuse
- Use of an investigational agent within 30 days of study entry
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: 1
P-containing meal alone
|
|
Active Comparator: 2
P-containing meal AND single 1 g oral dose of chewed lanthanum carbonate
|
single 1 g oral dose of lanthanum carbonate either chewed or crushed into a fine powder
|
Active Comparator: 3
P-containing meal and single 1 g oral dose of lanthanum carbonate crushed into a fine powder
|
single 1 g oral dose of lanthanum carbonate either chewed or crushed into a fine powder
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Serum phosphorous concentration
Time Frame: Hourly from time=0-8 h after administration of meal and drug
|
Hourly from time=0-8 h after administration of meal and drug
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Alan H Lau, Pharm.D., University of Illinois at Chicago
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2006-0530
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperphosphatemia in Chronic Kidney Disease
-
Astellas Pharma IncCompletedChronic Kidney Disease Patients on Hemodialysis With HyperphosphatemiaJapan
-
Novartis PharmaceuticalsCompletedHyperphosphatemia Patients With Chronic Kidney Disease on 3x/Week Replacement TherapyGermany, United Kingdom, Italy, Belgium, Sweden, Canada, United States, Australia, Finland, France, Norway, Puerto Rico, Switzerland
-
Astellas Pharma IncCompletedChronic Kidney Disease | Hyperphosphatemia Undergoing HemodialysisJapan
-
Keryx BiopharmaceuticalsRecruitingHyperphosphatemia Related to Chronic Kidney DiseaseUnited States
-
ArdelyxCompletedHyperphosphatemia | Chronic Kidney Disease Requiring Chronic DialysisUnited States
-
Vifor Fresenius Medical Care Renal PharmaCompletedHyperphosphatemia | Chronic Kidney Disease Requiring Chronic DialysisChina
-
Kissei Pharmaceutical Co., Ltd.CompletedChronic Kidney Disease Requiring HemodialysisJapan
-
Panion & BF Biotech Inc.Shandong Weigao Panion Pharmaceutical Co. Ltd.CompletedEnd Stage Renal Disease | ESRD | HyperphosphatemiaChina
-
Chugai PharmaceuticalCompletedHyperphosphatemiaUnited States
-
Genzyme, a Sanofi CompanyCompletedChronic Kidney Disease | HyperphosphatemiaUnited States, France, Germany, Lithuania, Poland
Clinical Trials on Lanthanum carbonate (chewed vs. crushed)
-
University of Illinois at ChicagoShireCompletedHyperphosphatemia | Kidney DiseaseUnited States
-
University of Wisconsin, MadisonShireCompleted
-
ShireCompletedEnd Stage Renal DiseaseUnited States
-
ShireCompleted
-
ShireCompleted
-
ShireCompletedHyperphosphatemiaUnited States, Germany, United Kingdom
-
Universitair Ziekenhuis BrusselRecruitingNephrolithiasis | Secondary HyperoxaluriaBelgium
-
ShireCompleted
-
BayerCompleted